Skip to content
DataLookout
Menu

NCT07906262

Efficacy of Rimegepant 75 mg for the Acute Treatment of Migraine: a Bayesian Individual Participant Data Meta-analysis Standardized to Defined Target Populations

StatusActive, Not Recruiting
PhaseNot specified
SponsorPfizer
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Pain Freedom at 2 Hours Postdose
Timeframe: 2 hours after administration of study treatment
Freedom From the Most Bothersome Symptom at 2 Hours Postdose
Timeframe: 2 hours after administration of study treatment
Pain Relief at 2 Hours Postdose
Timeframe: 2 hours after administration of study treatment

Secondary (15)

Pain Freedom at 1 Hour Postdose
Pain Relief at 1 Hour Postdose
Return to Normal Function at 1 Hour Postdose
Return to Normal Function at 2 Hours Postdose
Sustained Pain Freedom From 2 to 24 Hours Postdose
Show 10 moreShow less
Sustained Pain Freedom From 2 to 48 Hours Postdose
Sustained Pain Relief From 2 to 24 Hours Postdose
Sustained Pain Relief From 2 to 48 Hours Postdose
Freedom From Nausea at 1 Hour Postdose
Freedom From Nausea at 2 Hours Postdose
Freedom From Photophobia at 1 Hour Postdose
Freedom From Photophobia at 2 Hours Postdose
Freedom From Phonophobia at 1 Hour Postdose
Freedom From Phonophobia at 2 Hours Postdose
Rescue Medication Use Within 24 Hours Postdose

Arms and interventions

Rimegepant 75 mg

Participants from the included randomized, double-blind, placebo-controlled clinical trials who were randomized to receive rimegepant 75 mg for the acute treatment of a moderate or severe migraine attack.

Placebo

Participants from the included randomized, double-blind, placebo-controlled clinical trials who were randomized to receive placebo for the acute treatment of a moderate or severe migraine attack.

Drugs: Rimegepant, Placebo

Sites

1 site in 1 country

  • PfizerNew York, New York, United States